Cytochroma have initiated a Phase II clinical trial of Vitamin D analog CTA018 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).
Filed under: Uncategorized Tagged: | CTA-018, CTA018, Cytochroma, Vitamin D
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
Connecting to %s
Notify me of follow-up comments via email.
Get every new post delivered to your Inbox.
